ARTS-based peptides promote apoptosis of cancer cells
Introduction
Apoptosis, or programmed cell death plays a critical role in development and homeostasis (1) . Deregulation of the apoptotic process leads to various diseases and the inhibition of apoptosis is the hallmark of most if not all cancer cell types (2) . The main executioners of apoptosis are caspases, a family of cysteine proteases that preferentially cleave substrates after aspartate (3) . Caspases can be activated either through binding of ligands to cell-surface death receptors or through promoting the release of pro-apoptotic proteins from mitochondria (4) .
The apoptotic process is tightly controlled through the action of both activators and inhibitors of caspases (5) . Inhibitor of Apoptosis (IAP) are a family of proteins which can directly bind and inhibit caspases (6) . All IAP proteins are structurally related and contain at least one baculovirus IAP repeat (BIR) domain, which is required for binding to caspases (7) . Some of the IAP proteins contain a RING domain which bestows an E3-ubiquitin ligase activity (8) .
X-linked IAP (XIAP) is the best characterized IAP and probably the most potent inhibitor of caspases (9, 10) . XIAP contains a RING domain with an E3-ligase activity, ubiquitin associated domain and three BIR domains that can directly inhibit caspases-3, -7 and -9 (11, 12) .
In dying cells, the inhibition of caspases by XIAP is overcome to enable the initiation of apoptosis. This is achieved by the function of natural IAP-antagonist proteins. Several mammalian XIAP antagonists have been identified, including Smac/DIABLO (here forth referred to as Smac) (13, 14) , Omi/HtrA2, (15, 16) and ARTS (17, 18) . Most known mammalian IAP-antagonists including Smac and Omi/HtrA2 contain a short, conserved IAP-Binding-Motif (IBM) and are released to the cytosol upon apoptotic induction (reviewed in (8) ). This IBM, was originally described in Drosophila IAP-antagonists Reaper, Hid and Grim (19, 20) .
Drosophila IAP-antagonists as well as mammalian IAP-antagonists use their N-terminal IBM for IAP-binding and inhibition. This conserved four-residue motif (AVPI/F) binds to the surface groove on the BIR domains of the IAP proteins where caspases also bind and allows the release and activation of caspases (21) .
Another natural IAP antagonist is ARTS (Sept4_i2) (17) . ARTS is localized at the mitochondrial outer membrane (MOM) (22) . Upon induction of apoptosis, ARTS translocates from the mitochondria to the cytosol and antagonizes XIAP, causing activation of caspases and cell death (18, 23) .
Translocation of ARTS from MOM precedes the pore opening during mitochondrial outer membrane permeabilization (MOMP) which allows the release of Smac and Cytochrome c residing at the intermembrane space (IMS) (22) . Moreover, ARTS seems to be required for MOMP and the release Cytochrome c and Smac, as HeLa cells in which ARTS expression is knocked-down exhibit a significant inhibition in MOMP and release of these proteins (22) . Although ARTS lacks any recognizable IBM, ARTS can bind directly to BIR3 domain of XIAP and promote apoptosis (17, 18, 24) . ARTS is derived from the human septin gene Sept4 (17) . ARTS-based peptides promote apoptosis of cancer cells 5 subsequently have been implicated in diverse functions, including determination of cell polarity, cytoskeletal reorganization, membrane dynamics, vesicle trafficking, and exocytosis (25) . ARTS is exceptional both in terms of its mitochondrial localization and its pro-apoptotic function, not shared by any other known septin family member (26, 27) . ARTS expression is frequently lost in Acute Lymphoblastic Leukemia (ALL), lymphoma and hepatocellular carcinoma (HCC) patients, suggesting it functions as a tumor-suppressor protein ((28) and H. Steller personal communication). Moreover, Sept4/ARTS-deficient mice reveal increased numbers of hematopoietic stem and progenitor cells and elevated XIAP protein levels, increased resistance to cell death and augmented tumor incidence (29) . Importantly, the apoptosis, stem cell and tumor phenotypes of Sept4/ARTS-null mice are all suppressed by inactivation of XIAP. These findings confirm that XIAP is a major target for ARTS-induced caspase activation and tumor suppression (29) .
Since IAPs are over-expressed in a variety of tumors, these proteins have become attractive targets for designing new anti-cancer therapeutics (30, 31) . In vivo and in vitro studies have demonstrated that downregulation of XIAP potentiates apoptosis in different tumors (32, 33) and anti-sense oligonucleotides or RNAibased technologies can be used for this purpose (34, 35) .
Another strategy to antagonize IAP proteins is by using IBM peptido-mimetics, which mimic one (monovalent) or two IBM sequences in tandem (bivalent) (36, 37) . These compounds sensitize cancer cells to apoptosis due to elimination of XIAP-mediated caspase inhibition as well as proteasomal degradation of the cIAP and activation of NF-K B pathway (38, 39) .
In this study we show that ARTS can preferentially kill cancer cells. The binding of ARTS to XIAP involves sequences that are distinct from all other known IAP-antagonists. ARTS does not contain the canonical IBM and binds to XIAP via a unique sequence which we term ARTS-IBM (AIBM). This AIBM sequence is sufficient to bind XIAP and promote apoptosis. Moreover, AIBM-based peptides can bind to BIR3/XIAP and reduce XIAP levels inducing apoptosis in a mechanism similar to function of full length ARTS protein. These peptides penetrate cancer cells, induce caspase activation and apoptosis. These results provide proof of concept for developing ARTS-based cancer therapeutics.
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Experimental Procedures Antibodies
Antibodies to the various proteins were purchased from the indicated companies, and used as instructed.
Importantly, unless noted otherwise, in all our assays we used the monoclonal anti-ARTS antibody (Sigma, St. Louis) which is the only currently commercially available antibody directed against the unique C-terminus of ARTS. Antibodies against GST (B-14, sc-138, Santa Cruz), H2AX (DR1016, Calbiochem), XIAP (#610716, BD), cIAP (AF818, R&D systems), caspase-9 (c7729, Sigma; #9502, Cell Signalling), caspase-3 (5A1E, Cell Signaling; #9661, Cell Signaling), cleaved PARP (D64E10, #5625, Cell Signalling) and actin (c4, #691001, MP) were used.
Constructs
The pSC2-6myc-ARTS construct with 6myc tag which was attached to the N-terminus of ARTS, was generated using PCR with the following primers:
F BamHI-5'-EcoRI 5'-CGAATTCCATGATCAAGCGTTTC-3' and the reverse primer: pEG-ARTS-R XhoI 5'-TACCGCTCGAGCTAGTGGCAGCCCTGCCC-3'. For the GST-pull-down assays, we cloned full-length ARTS into the pGEX4T (Pharmacia Biotech) construct; GST-ARTS fusion protein was generated using PCR method with the following primers:
BamHI-5'-TCGAGGATCCATCAAGCGTTTCCTGGAGGACACCACGG-3' and EcoRI-5'-CTAGTGGCAGCCCTGCCCCTGGTGC-3', and cloned into BamHI and EcoRI sites in pGEX4T. The pEBG expression constructs encoding N-terminus GST fusion proteins together with XIAP-BIR3 were a kind gift from Colin Duckett.
Peptide synthesis labeling and purification
Pep1 -YGPSLRLLA, Pep2 -PPGAVKGTG, Pep3 -QEHQGQGCH.
The peptides were synthesized, labeled, purified and analyzed as described in (42) .
Mammalian cell culture
COS-7 and HeLa cells were grown in Dulbecco's modified Eagle medium (DMEM) with 4.5g/l D-glucose.
K562 and CCRF-CEM cells were grown in RPMI medium. Media were supplemented with 10% fetal calf serum (FCS), penicillin 100U/ml, streptomycin 100mg/ml, and glutamine 2mM (Biological Industries, Israel).
All other cell lines were purchased from ATCC and growth media was used according to ATCC instructions. 
Western blot analyses
Western blot analyses were performed as described in (23) . Visualization was performed using LAS4000 luminesent image analyzer (Fujifilm). For densitometry analyses intensity of signals was compared to actin using TotalLab TL100 graphic software (Nonlinear Dynamics Ltd).
Immunofluorescence assay
Immunofluorescence assay was carried out as described in (23) .
Image analysis was carried out using confocal laser microscopy (Zeiss LSM 510) or fluorescent microscopy (Nikon 50i).
Binding assays
In vivo GST pull-down binding studies. COS-7 cells were co-transfected with pEBG-empty vector or pEBG-XIAP-BIR3 together with pCS2-6myc-ARTS or pCS2-6myc-vector. The cells were lysed in RIPA buffer (150mM NaCl, 50mM Tris-HCl (pH8), 1% NP-40, 0.5% deoxycholate acid containing protease inhibitors (mini Complete, Roche)). The samples were left rotating for 4 hours at 4°C with the GST fusion proteins coupled to the glutathione beads. Samples were centrifuged at 4000 rpm at 4°C for 4 minutes and washed five times in lysis buffer. Proteins were eluted from beads following 5min of boiling in sample buffer. Proteins were separate on 12.5% SDS-PAGE gel, followed by Western blot analysis.
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on April Biosciences) . Samples were centrifuged at 4000 rpm at 4°C for 5min and washed three times in PBS. Proteins were eluted from beads following 5min of boiling in sample buffer. Proteins were separate on 12.5% SDS-PAGE gel, followed by Western blot analysis.
In vivo co-immunoprecipitation of ARTS-derived peptides. HeLa or COS-7 cells were transfected with pEBG-XIAP-BIR3 or pEBG-cIAPI or pEBG empty vector. Cell lysates were incubated with the indicated peptides for 3h, followed by GST-pull down using glutathione beads for additional 2h. After three washes, fluorescence emission was measured using a fluorimeter reader (Enspire 2300 multilabel reader, Perkin Elmer).
Mortality assay
K562 cells were incubated in 24-well plate at 0. Research. 
Results

ARTS can preferentially kill cancer cells
Over-expression of ARTS alone is sufficient for induction of apoptosis in several tumor cell lines (18, 23, 28) .
Expression of ARTS is frequently lost in Acute Lymphoblastic Leukemia (ALL) and lymphoma patients (28) .
Moreover, Sept4/ARTS-deficient mice exhibit increased incidence of spontaneous tumors and accelerated tumor development in an Eµ-Myc background (29) . Together these data suggest that loss of ARTS can provide a survival advantage for tumor cells and that treating cancer cells with ARTS-mimetics might restore the ability of cancer cells to undergo apoptosis. Therefore, we first decided to investigate whether exogenous ARTS can selectively affect cancer but not normal cells. For this purpose, we used electroporation to introduce exogenous ARTS into ARH77 multiple myeloma cells and into normal lymphocytes isolated from healthy donors. TUNEL assay was performed in these cells to determine apoptosis. Despite high expression levels of exogenous ARTS in normal lymphocytes, no increase in apoptosis was seen in these cells when compared to transfection with control vector ( Figure 1A left panel, Figure 1B ). In contrast, despite equivalent expression levels of exogenous ARTS detected in ARH77 multiple myeloma cells, a prominent increase in apoptosis was shown in these cancer cells ( Figure 1A right panel, Figure 1B ). These results suggest that exogenous ARTS can preferentially kill cancer cells without causing significant toxicity to normal cells.
The unique C-terminal domain of ARTS is sufficient to bind to XIAP-BIR3 and induce apoptosis
The main mechanism by which ARTS promotes apoptosis is through binding and antagonizing XIAP (18) . In addition, we have recently discovered that ARTS binds specifically to the BIR3 domain in XIAP ( Figure 2AI and (24) . IAP antagonists in Drosophila -Reaper, Hid and Grim, use a conserved N-terminal IAP Binding Motif (IBM) for binding and induction of apoptosis (19, 20) . This IBM is necessary and sufficient for IAP inhibition and it is conserved amongst all other known IAP-antagonists, including mammalian Smac and Omi/HtrA2 (13, 14, 21, 40) . ARTS lacks any recognizable IBM. Instead, ARTS contains a stretch of 27 residues at its C-terminus, which is not found in any other known protein (17, 18) . Sept4_i1 (H5/PNUTL2), is the other splice variant of Sept4 gene (26, 41) . Although Sept4_i1 shares 83% amino acid identity with ARTS, it does not contain the 27mer C-terminal domain of ARTS (ARTS-CTD) and cannot induce apoptosis (28) .
Therefore, we reasoned that this unique ARTS-CTD may be important for its pro-apoptotic function and IAPbinding. To test this hypothesis, we investigated whether the 27mer motif alone is sufficient to bind BIR3/XIAP and to induce apoptosis in different cell lines. Indeed, expression of the myc-tagged C-terminal 27 residues of ARTS was sufficient for binding to BIR3/XIAP ( Figure 2AII ). This construct was able to promote apoptosis in leukemia K562 and cervical carcinoma HeLa cells as efficiently as the full-length ARTS ( Figure   2BI , 2BII). In addition, ARTS-CTD construct specifically reduced the levels of XIAP but not cIAP1 in these cells ( Figure 2BII ). Similar results exhibiting specific reduction of XIAP but not cIAP1 were seen following 
transfection of full length ARTS in HeLa cells (22) . This suggests that similar to the full length ARTS, the ARTS-CTD construct can promote activation of caspase-3 and an increase in levels of the apoptotic marker H2AX through degradation of XIAP. Because these 27mers bear no similarity with other IAP-binding proteins and lack any detectable IBM consensus sequences, it appears that ARTS contains a novel IAP-binding motif, which we will here forth refer to as ARTS-IAP binding motif (AIBM).
AIBM 9aa peptide derivatives can bind to XIAP-BIR3
We have found that ARTS specifically binds to the BIR3 domain in XIAP (24) . In addition, NMR analysis of ARTS-CTD bound to BIR3/XIAP revealed that the last third of ARTS-CTD is particularly important for that binding (42) . To investigate which of the residues in AIBM could substitute the function of the full length ARTS protein, we subdivided the 27mer AIBM into three non-overlapping 9mer peptides (ARTS 248-256, ARTS 257-265 and ARTS 266-274), termed Pep1, Pep2, and Pep3 respectively ( Figure 3A ). These peptides were labeled with fluorescein as well as the 27mer AIBM (ARTS 248-274). Since the 27mer AIBM construct could bind to BIR3/XIAP, it served as a positive control in this assay (Figure 2A ). The ability of the peptides to bind to BIR3/XIAP was examined. Incubation of the fluorescein-labeled 9mer peptides with COS-7 cells expressing BIR3/XIAP-GST resulted in efficient uptake of these peptides without any further treatment ( Figure 4A) . Moreover, as shown in Figure 3B , co-immunoprecipitation with anti-fluorescein antibodies revealed that the AIBM peptide as well as its derivatives, Pep2 and Pep3, can bind to BIR3/XIAP. Pep3 showed highest binding to BIR3/XIAP ( Figure 3BII ). In addition, we found that Pep3 can also bind to cIAPI, although to a lesser extent than to BIR3/XIAP (Supplementary Figure S3) .
AIBM based peptides reduce XIAP levels and induce apoptosis in cancer cells through activation of caspase-9 and caspase-3
In order to explore whether the ARTS-derived AIBM peptides can penetrate and kill cancer cells, K562 leukemia cells were incubated with the fluorescein-labeled peptides and apoptosis was determined using TUNEL assay. All three fluorescein-labeled 9mer peptides were able to penetrate K562 cells with high efficiency ( Figure 4A ). However, only Pep2 and Pep3 which could bind to BIR3/XIAP in immunoprecipitation assays, were also able to induce cell death as visualized by increased numbers of TUNEL positive cells ( Figure 4A ). Pep3 exhibited the strongest ability to potentiate apoptosis in K562 leukemia cells Figure S2) . Similar results were obtained using cell mortality assays ( Figure 4C, Supplementary Figure S2 ). Pep3 was also most potent in promoting caspase-3 activity (Figure 5A ), caspase-9 activity ( Figure 5B ) and in reducing XIAP levels ( Figure 5C ). Similar results were obtained when using CCRF-CEM T-cell leukemia cell line (Figure 6 ). In summary, AIBM derivatives Pep2 and Pep3 which can bind to XIAP also showed efficient cell killing of K562 and CCRF-CEM cancer cell lines (Figure 4-6) . The ability of AIBM derivatives to bind XIAP seems to be linked with their pro-apoptotic activity, as a mutated Pep3 (H248A Pep3) with impaired binding to BIR3/XIAP (42) had compromised cell killing activity (Supplementary Figure S2) . In all these assays, Pep3 was the most potent inducer of cell death (Figures 5-6) , with highest ability to reduce XIAP levels in both CCRF-CEM and K562 cells (Figure 5E, 6B) . Importantly, the AIBM derived Pep2 and Pep3-induced apoptosis involved activation of caspase-9 and caspase-3, and reduction of XIAP levels ( Figure 5B, 5C, 6B ).
To test whether AIBM-derived peptides have general cytotoxicity, we tested Pep3 on several other cancer cell lines. We found that Pep3 could also promote apoptosis in HeLa cells, but three other cancer cell lines -T98G, a human glioblastoma line; DU145, a human prostate carcinoma cell line; and PANC1, a human pancreatic cancer cell line -were completely non-responsive (data not shown). Therefore, Pep3 does not appear to cause general, unspecific cell death. This suggests that, despite their small size, AIBM-based 9mer peptides retain at least some of the pro-apoptotic activity of full-length ARTS and may therefore specifically 
Discussion
In recent years, IAP proteins have emerged as promising targets for cancer therapy (31, 36, 37) . XIAP is considered to be the most potent inhibitor of caspases in vitro and elevated levels of this protein are found in human tumors (10, 30, 31) . On the other hand, because mice deficient for XIAP are viable, the physiological function of XIAP in situ has remained unclear. However, it was shown that loss of XIAP function causes elevated caspase-3 enzyme levels and sensitizes certain primary cells towards apoptosis (9) . In addition, XIAP-mutant mice are protected against Eµ-Myc-driven lymphoma due to increased apoptosis of premalignant lymphocytes (9, 43) . Conversely, loss of ARTS function has been implicated in hematopoietic malignancies (28) and Sept4/ARTS-deficient mice develop spontaneous hematopoietic malignancies (29) .
Moreover, these Sept4/ARTS-null mice exhibit elevated XIAP protein levels and increased resistance to cell death (29) . Importantly, the tumor and apoptosis phenotypes of Sept4/ARTS-deficient mice are all suppressed by inactivation of XIAP. These findings confirm that XIAP is a major target for ARTS-induced caspase activation and tumor suppression (29) .
Several approaches for developing anti-cancer drugs have focused on specifically antagonizing XIAP (44).
These approaches include anti-sense oligonucleotides or RNAi-based technologies selectively inhibiting expression of XIAP (34, 35) . In addition, small molecules mimicking IBM domain were designed and tested in clinical trials (36, 37, 39, (45) (46) (47) .
Over-expression of ARTS can promote apoptotic cell death in a variety of cancer cell lines (18, 23) , but seems to have no effect on normal lymphocytes (Figure 1) . Moreover, certain cancer cell lines such as human glioblastoma (T98G), prostate carcinoma (DU145) and pancreatic cancer cell line (PANC1) were completely non-responsive to Pep3 administration, suggesting that the effect of ARTS is selective and not due to general cytotoxicity.
We have recently shown that ARTS initiates caspase activation upstream of MOMP (22) . ARTS is localized at the outer membrane of mitochondria (MOM) (22) . Following induction of apoptosis, ARTS rapidly translocates to the cytosol where it binds to XIAP. The translocation of ARTS from mitochondria occurs within minutes following apoptotic stimuli and precedes MOMP and the release of cytochrome C and SMAC seen hours after induction of apoptosis (22) . Moreover, knockdown of ARTS strongly inhibits the release of SMAC and cytochrome C, suggesting that ARTS is required for the proper timing of MOMP and the release of these proteins (22) . We therefore propose that ARTS-based mimetics could be useful in initiating apoptosis in cancer cells.
In an effort to better define the binding site of ARTS to XIAP and explore the feasibility of developing ARTSmimetics, we initiated structure-function analyses. We found that the 27 residues covering the unique Cterminus of ARTS are sufficient for binding to XIAP and inducing apoptosis similar to full-length ARTS (Figure 2 ). Since the 27 residues residing at the extreme C-terminus of ARTS show no detectable sequence similarity to any known motif and have a composition entirely distinct from the IBM, we conclude that it contains a novel IAP binding motif, that we term ARTS-IAP-Binding-Motif (AIBM). Of notice, deletion of these 27 residues did not completely abrogate the ability of ARTS to bind to XIAP (data not shown).
However, deleting 68 residues from the C-terminus of ARTS abolished the ability of ARTS to bind to XIAP (18) . We therefore suggest that the unique 27 residues of ARTS are sufficient for binding of ARTS to XIAP but there are probably additional residues which are needed for a better, more efficient binding. A somewhat similar situation is seen for the IBM. Although the pro-apoptotic function of Smac requires a conserved four residue IBM (AVPI), additional residues downstream make a second contact with the XIAP-BIR3 domain (13, 14, 21, 48) . Similarly, the Drosophila IBM containing proteins, Reaper/Hid/Grim use sequences beyond the 5th amino acid to bind to Diap1 (48) . However, the significance of additional residues for binding to XIAP beyond the 27 residues comprising the unique C-terminus of ARTS, awaits further structural analysis studies using X-ray crystallography.
Importantly, NMR analyses revealed that BIR3/XIAP interacts with C-terminal part of AIBM (42) . These data support our results showing that Pep3 located at the very C-terminal part of AIBM is most potent in binding and promoting apoptosis ( Figures 3B, 4-6 ). In addition, two different studies have recently described the properties of the unique C-terminus of ARTS using various biochemical and structural methods, including CD and NMR (27, 42) . Based on these studies it appears that the C-terminus of ARTS is highly disordered. Moreover, these studies indicate that peptides derived from the C-terminal domain of ARTS are intrinsically disordered and lack significant secondary structure (27, 42) . Pep3 was found to be the most potent activator of caspase-9 and caspase-3 ( Figure 5-6 ). Pep2 showed variable potency in killing cancer cells (Figures 4-6) . We speculate that these variable results may reflect the different sensitivities of the different experimental methods used. Alternatively, this may support our hypothesis that residues outside of Pep3 are also important for binding and induction of apoptosis.
ARTS was shown to promote apoptosis through specifically inducing proteasome-mediated degradation of XIAP (18, 49) . Similarly, we now show that Pep3 promotes down-regulation of XIAP levels ( Figures 5C, 6C , Supplementary Figure S1 ) in a caspase independent manner (Supplementary Figure S1) . Therefore, degradation of XIAP following peptide administration is not a consequence of general apoptosis, but rather directly induced by these peptides. This reduction of XIAP levels is associated with caspase activation and induction of apoptosis (Figures 4, 5A-B, 6A-B) . ARTS was shown to bind to other IAP family members such as cIAPI (22) . Similarly, while Pep3 shows highest binding to BIR3/XIAP, it also binds to cIAPI, although to a lesser extent (Supplementary Figure S3) . Thus, we cannot rule out that the AIBM derivatives may have additional targets such as other members of IAP family and/or that they could activate other apoptosis pathways in addition to targeting XIAP in a way that full-length ARTS does. scrambled peptide which had no effect on the cells. XIAP levels were determined by Western blot analysis.
Densitometry analyses were performed using TotalLab TL100 graphic software, measurements are presented relative to actin levels, which served as loading control (mean±SEM, n=4). A. CCRF-CEM T-cell leukemia cells were incubated with AIBM-derived 9mer peptides (Pep1, Pep2, Pep3) for 24h, followed by Western blot analyses. Scrambled peptide was used as a control. Apoptosis was detected by determining the levels of phosphorilated H2AX and cleaved PARP (cPARP). Pep2 and Pep3 induced a potent apoptotic response in CCRF-CEM cells as evident by a strong increase in H2AX and cPARP levels. B.
Pep2 and Pep3 induces caspase-9 and caspase-3 cleavage and activation. CCRF-CEM cells were incubated with AIBM-derived peptides for 24h. Scrambled peptide was used as a control. The levels of cleaved caspase-9 (cCasp9) and cleaved caspase-3 (cCasp3) were determined using Western blot analysis. Pep2 and Pep3 induced a significant increase in activation of caspase-3 and caspase-9 in CCRF-CEM cancer cells. C. Pep2 and Pep3 cause reduction of XIAP levels in CCRF-CEM cancer cells. CCRF-CEM cells were incubated with either Pep1, Pep2 or Pep3 or with scrambled control peptide that has no effect, for 24h. XIAP levels were determined by Western blot analysis. Densitometry analyses were performed using TotalLab TL100 graphic software, measurements are presented relative to actin levels, which served as loading control (mean±SEM, n=4). 
